Account
News
30.04.2019
How pharmacist biosimilar substitution would work

The law provides a legal framework for the automatic substitution of biosimilars at the level of the...

Read more
News
10.04.2019
The Orkambi blame game

The deadlock between Vertex and NHS over the cystic fibrosis drug Orkambi was played out in a parlia...

Read more
News
08.04.2019
UK pharma negotiating choppy seas during Brexit

The ABPI is working closely with the Department of Health and Social Care, NHS England and NICE to e...

Read more
News
02.04.2019
Kymriah - a tale of two indications

NICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...

Read more
News
29.03.2019
Canadian government to make prescriptions more aff

Canadians pay too much for prescription drugs – and that means far too many go without the medicin...

Read more
News
26.03.2019
National body ensures CCG decisions are consistent

Following a series of FOI requests to CCGs, MTG said a number of CCGs are currently restricting acce...

Read more
News
20.03.2019
NICE approve Almirall's Ilumetri

Initially NICE rejected Illumetri for not being cost-effective, but a new negotiated price means th...

Read more
News
19.03.2019
NICE suggest industry must align

Speaking at the international pharma conference, NICE’s chief executive Sir Andrew Dillon struck a...

Read more
News
15.03.2019
SMC says no to Novartis' Kymriah

Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scot...

Read more
News
14.03.2019
Tecentriq gains first IO approval

Roche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.